New Advance in Antiviral Drug Design
A topical collection in Biomedicines (ISSN 2227-9059). This collection belongs to the section "Immunology and Immunotherapy".
Viewed by 363Editor
Interests: cheminformatics; bioinformatics; drug design; SARS-CoV-2 M-pro inhibitors
Special Issues, Collections and Topics in MDPI journals
Topical Collection Information
Dear Colleagues,
In wake of the formidable challenges posed by the global SARS-CoV-2 pandemic, the requirement for innovative antiviral drug design has never been more pressing. As we stand at the crossroads of scientific advancement, the need to fortify our arsenal against not only the current coronavirus, COVID-19, but also potential future viral infections has become abundantly clear. This Special Issue, titled "New Advances in Antiviral Drug Design," serves as an example of the latest advancements in the field. It aspires to amalgamate an array of research articles and reviews that shed light on compounds and extracts exhibiting remarkable inhibitory potential against coronaviruses and other viruses alike. This Special Issue also embraces the development of cutting-edge computational techniques that will revolutionize efficacy prediction for novel antiviral compounds. While the creation of effective antiviral agents is beset by intricate challenges, including viral mutability and host specificity, this collection aims to shed light on the remarkable efforts of scientists in overcoming these hurdles.
By fostering a deeper understanding of the complexities underlying antiviral drug design, this Special Issue seeks to propel the scientific community toward more robust, adaptable, and preemptive strategies for combating viral outbreaks on a global scale.
Dr. Santiago Garcia-Vallve
Collection Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug design
- antiviral immunity
- antiviral drugs
- medicinal chemistry
- targeted covalent inhibitors
